KUALA LUMPUR: CGS-CIMB Equities Research is maintaining its Add call for Duopharma Biotech with a lower target price of RM1.90 compared with the earlier RM2.03.
It said on Friday in tandem with its reduction in the EPS, it lowered it TP to RM1.90, still based on 16 times CY21F P/E, in line with its five-year historical mean.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!